Acelyrin Inc Net Income per Employee (SLRN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Acelyrin Inc   (NASDAQ: SLRN)
 

Acelyrin Inc Net Income per Employee

SLRN's Quarterly Results, Trends, Rankings, Statistics
Acelyrin Inc recorded a cumulative net loss of $-269 million during 12 month ending in the first quarter 2025.
The Healthcare sector has seen employees of 270 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3613, from total ranking in previous quarter at 3701.


What is Income per Employee Ratio?






SLRN Net Income per Employee (Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,329,292 -1,228,842 -1,308,936 -1,484,144 -1,188,931
SLRN's Total Ranking # 3613 # 3701 # 3402 # 2716 # 0
Seq. Net Income Change - - - - -


SLRN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 271
Healthcare Sector # 643
Overall Market # 3613

Net Income per Employee Statistics
High Average Low
$ -128,906 $ -1,178,985 $ -1,889,312
(Jun 30 2023)   (Dec 31 2023)







Companies with similar Income per Employee for 12 month ending Mar 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2025Number of Employees Mar 31 2025


Date modified: 2026-08-29T17:48:17+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.